The FDA has granted priority review of the supplemental New Drug Application for ruxolitinib for the treatment of steroid-refractory chronic graft-versus host disease (GVHD).
The FDA has granted priority review of the supplemental New Drug Application (sNDA) for ruxolitinib (Jakafi) for the treatment of steroid-refractory chronic graft-versus host disease (GVHD) in adults and children age 12 years and older. In 2019, the drug was approved to treat steroid-refractory acute GVHD in the same population.
At the American Society of Hematology (ASH) Annual Meeting & Exposition, held in December 2020, Incyte had released the results of the REACH3 trial,1 which are being used as part of the sNDA submission. The trial was a randomized study comparing ruxolitinib with the best available therapy (BAT) in patients with steroid-refractory chronic GVHD.
“Chronic GVHD is a life-threatening complication following stem cell transplant that burdens a vulnerable patient population, which today has limited treatment options,” Peter Langmuir, MD, group vice president, oncology targeted therapies, Incyte, said in a statement. “The acceptance of this sNDA represents an important milestone for Incyte as we continue our work towards helping more people living with GVHD, particularly for those who do not respond to steroids.
In the trial presented at ASH, 329 patients were randomized to receive either ruxolitinib (n = 165) or BAT (n = 164). In the overall trial, 48% of patients had moderate chronic GVHD and 52% had severe chronic GVHD. As of May 8, 2020, 50% of the patients had discontinued ruxolitinib compared with 74% who discontinued BAT; in addition, 61 patients (37%) had crossed over from the BAT arm to the ruxolitinib arm. Patients taking BAT were allowed to crossover to the ruxolitinib arm on or after cycle 7 day 1 (C7D1) if they did not achieve or maintain complete response or partial response, developed toxicity to BAT or had a chronic GVHD flare.
According to the researchers, ruxolitinib demonstrated a superior efficacy. Failure-free survival (FFS) was significantly longer for patients treated with ruxolitinib: the median FFS was not reached for the ruxolitinib arm compared with 5.7 months for the BAT arm (HR, 0.370 [95% CI, 0.268-0.510]; P < .0001).
Ruxolitinib also had a superior overall response rate (ORR) at week 24, the primary end point of the trial. The ORR for patients taking ruxolitinib was 50% vs 26% for the BAT arm (odds ratio, 2.99; P < .0001).
“Based on the compelling REACH3 results, we now have a potential new standard of care for these patients,” presenting author Robert Zeiser, MD, of the University Hospital Freiburg, in Freiburg, Germany, said in a statement at the time the paper was presented at ASH.
The target Prescription Drug User Fee Act action date for Jakafi is June 22, 2021.
Reference
Zeiser R, Polverelli N, Ram R, et al. Ruxolitinib (RUX) vs best available therapy (BAT) in patients with steroid-refractory/steroid-dependent chronic graft-vs-host disease (cGVHD): primary findings from the phase 3, randomized REACH3 study. Presented at the 62nd American Society of Hematology Annual Meeting and Exposition, Virtual; December 5-8, 2020; Abstract 77.
Atypical Marker Expression in T-Cell Acute Lymphoblastic Leukemia/Lymphoma
May 15th 2024Two unique case reports highlight the diagnostic challenges and critical importance of comprehensive immunophenotyping in cases of T-cell acute lymphoblastic leukemia/lymphoma that present without typical immaturity markers but with rare γδ T-cell receptor expression.
Read More
Frameworks for Advancing Health Equity: Urban Health Outreach
May 9th 2024In the series debut episode of "Frameworks for Advancing Health Equity," Mary Sligh, CRNP, and Chelsea Chappars, of Allegheny Health Network, explain how the Urban Health Outreach program aims to improve health equity for individuals experiencing homelessness.
Listen
Patients With MG Report Higher Azathioprine Discontinuation vs Other Immunosuppressants
May 15th 2024Survey data from over 200 patients showed that treatment discontinuation was lower for those taking mycophenolate or methotrexate than for those taking azathioprine for their myasthenia gravis (MG).
Read More